Notify me when Tamarack Advisers, LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q4 2023 | 1 | $2.12M | $0 | -$45.4M | -$45.4M | STRM | 13F-HR | 2/8/2024, 05:42 PM |
| Q3 2023 | 14 | $50.2M | +$2.66M | -$70.4M | -$67.7M | VTRS, BDX, MDRX, MCK, STRM | 13F-HR | 11/15/2023, 09:55 PM |
| Q2 2023 | 30 | $132M | +$30.5M | -$35.5M | -$4.94M | VTRS, MDRX, PHR, COLL, THC | 13F-HR | 8/9/2023, 06:28 PM |
| Q1 2023 | 34 | $131M | +$31.8M | -$37.5M | -$5.69M | VTRS, MDRX, PHR, STRM, COLL | 13F-HR | 5/10/2023, 06:06 PM |
| Q4 2022 | 32 | $138M | +$32.2M | -$65.7M | -$33.5M | MDRX, VTRS, PHR, CERS, COLL | 13F-HR | 2/10/2023, 07:09 PM |
| Q3 2022 | 42 | $169M | +$47M | -$47.2M | -$296K | LNTH, MDRX, PCRX, PRGO, THC | 13F-HR | 11/14/2022, 07:12 PM |
| Q2 2022 | 39 | $172M | +$62.4M | -$66.8M | -$4.42M | CI, LNTH, CERS, PCRX, THC | 13F-HR | 8/15/2022, 06:39 PM |
| Q1 2022 | 42 | $209M | +$70.5M | -$108M | -$37M | CI, PCRX, LNTH, MRK, BVS | 13F-HR | 5/11/2022, 03:28 PM |
| Q4 2021 | 44 | $242M | +$89.4M | -$148M | -$58.7M | THC, PCRX, MDT, BVS, SIBN | 13F-HR | 2/11/2022, 07:04 PM |
| Q3 2021 | 36 | $312M | +$58.4M | -$83.4M | -$25M | HSIC, RIGL, MDT, PCRX, PDCO | 13F-HR | 11/10/2021, 06:30 PM |
| Q2 2021 | 40 | $349M | +$68.2M | -$235M | -$167M | MDT, RIGL, HSIC, PCRX, TPB | 13F-HR | 8/12/2021, 08:08 PM |
| Q1 2021 | 54 | $482M | +$128M | -$161M | -$33.3M | PCRX, MDT, RIGL, PDCO, TPB | 13F-HR | 5/11/2021, 08:31 PM |
| Q4 2020 | 38 | $470M | +$132M | -$42M | +$90.2M | PCRX, MDT, UTHR, RIGL, NUAN | 13F-HR | 2/9/2021, 05:32 PM |
| Q3 2020 | 29 | $319M | +$56.9M | -$96.7M | -$39.8M | PCRX, MDT, HOLX, PRGO, RIGL | 13F-HR | 11/10/2020, 08:19 PM |
| Q2 2020 | 29 | $348M | +$106M | -$86.3M | +$20.1M | PCRX, DGX, PRGO, UTHR, HOLX | 13F-HR | 8/10/2020, 06:07 PM |
| Q1 2020 | 30 | $260M | +$78.6M | -$179M | -$100M | DGX, MDT, ATRC, MDRX, PRGO | 13F-HR | 5/14/2020, 01:48 PM |
| Q4 2019 | 25 | $437M | +$87.5M | -$65.4M | +$22.1M | MDT, BIO, MDRX, ATRC, PCRX | 13F-HR | 2/10/2020, 08:48 PM |
| Q3 2019 | 25 | $382M | +$89.8M | -$31.7M | +$58.1M | MDRX, MDT, BIO, PCRX, PTLA | 13F-HR | 11/5/2019, 03:42 PM |
| Q2 2019 | 19 | $329M | +$111M | -$39M | +$71.6M | MDRX, MDT, BIO, PCRX, SRCL | 13F-HR | 8/12/2019, 04:58 PM |
| Q1 2019 | 20 | $251M | +$66M | -$88.7M | -$22.8M | MDRX, MDT, SRCL, PTLA, LNTH | 13F-HR | 5/13/2019, 03:29 PM |
| Q4 2018 | 20 | $245M | +$44.1M | -$80.7M | -$36.6M | MDRX, MDT, NUVA, ATRC, NXTM | 13F-HR | 2/11/2019, 05:25 PM |
| Q3 2018 | 24 | $348M | +$61.8M | -$54.7M | +$7.1M | NUVA, LH, MDRX, MDT, SRCL | 13F-HR | 11/13/2018, 01:26 PM |
| Q2 2018 | 25 | $297M | +$152M | -$67.4M | +$84.1M | MDT, NUVA, MDRX, LH, OPTN | 13F-HR | 8/14/2018, 12:53 PM |
| Q1 2018 | 27 | $210M | +$105M | -$70.9M | +$33.7M | NVCR, NUVA, MDRX, MDT, CORI | 13F-HR | 5/7/2018, 08:11 PM |
| Q4 2017 | 25 | $181M | +$52.3M | -$51.1M | +$1.12M | MDRX, PCRX, LH, NUVA, MDT | 13F-HR | 2/13/2018, 06:52 PM |
| Q3 2017 | 23 | $161M | +$45.7M | -$58.9M | -$13.3M | MDRX, NKTR, MDT, CORI, GILD | 13F-HR | 11/13/2017, 01:33 PM |
| Q2 2017 | 26 | $170M | +$30.3M | -$40.3M | -$10M | MDRX, NKTR, LH, PCRX, SPNC | 13F-HR | 8/7/2017, 06:30 PM |
| Q1 2017 | 31 | $160M | +$56.8M | -$54.3M | +$2.56M | MDRX, PCRX, NKTR, GILD, SPNC | 13F-HR | 5/12/2017, 03:55 PM |
| Q4 2016 | 27 | $141M | +$42.5M | -$207M | -$164M | ARIA, NXTM, HOLX, BIO, PCRX | Restatement | 2/16/2017, 03:04 PM |
| Q3 2016 | 31 | $314M | $0 | $0 | ELGX, NXTM, PDCO, ARIA, BIO | New Holdings | 11/9/2016, 06:44 PM | |
| Q3 2016 | 31 | $314M | +$88M | -$86.3M | +$1.71M | ELGX, NXTM, PDCO, ARIA, BIO | 13F-HR | 11/8/2016, 07:01 PM |
| Q2 2016 | 28 | $258M | +$64.8M | -$113M | -$47.8M | ELGX, NXTM, IMPR, ARIA, DGX | 13F-HR | 8/12/2016, 05:49 PM |
| Q1 2016 | 19 | $285M | +$34.8M | -$225M | -$190M | ELGX, DGX, PDCO, NXTM, MDRX | 13F-HR | 5/13/2016, 08:04 PM |
| Q4 2015 | 26 | $525M | $0 | $0 | PDCO, DGX, ELGX, NXTM, MDT | 13F-HR | 2/8/2016, 03:20 PM |